Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.
No clear dosing guidelines exist for cyclophosphamide (Cy) dose adjustments in obese patients treated with high-dose chemoradiotherapy followed by autologous hematopoietic cell transplantation (HCT). We prospectively compared the outcomes of high-dose Cy/total body irradiation (TBI) conditioning in 147 non-Hodgkin lymphoma (NHL) patients in 3 weight groups: nonobese (<120% ideal body weight [IBW]; n = 72), overweight (120% to 149% IBW; n = 46), and obese (≥150% IBW; n = 29). Nonobese and overweight patients received Cy (120 mg/kg of total body weight, intravenously) and TBI (1320 cGy), whereas obese patients (median body mass index, 36) received an adjusted Cy dose based on IBW plus 50% of the difference between total body weight and IBW (AdjBW50). The median patient age was 57 years (range, 19 to 73). The most common diagnoses were diffuse large B cell lymphoma (n = 57) and mantle cell lymphoma (n = 51). Three-year overall survival was 61% (95% confidence interval [CI], 48% to 72%) for nonobese patients, 68% (95% CI, 52% to 82%) for overweight patients, and 80% (95% CI, 62% to 93%) for obese patients. Cumulative incidence of relapse (48%, 43%, and 38%, respectively) and nonrelapse mortality (∼4%) were similar in all groups. Hemorrhagic cystitis and cardiac toxicity were rare events. Our data show that the AdjBW50 formula can be safely and effectively used for Cy dose adjustments in obese patients treated for NHL with high-dose Cy/TBI conditioning followed by autologous HCT.
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota. Electronic address: bach0173@umn.edu.
Veronika
V
Bachanova
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
John
J
Rogosheske
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Ryan
R
Shanley
National Marrow Donor Program, University of Minnesota, Minneapolis, Minnesota.
Linda J
LJ
Burns
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Sara M
SM
Smith
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Daniel J
DJ
Weisdorf
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Claudio G
CG
Brunstein
D000328:Adult; D000368:Aged; D064592:Autografts; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009765:Obesity; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide
Cyclophosphamide; Hematopoietic cell transplantation; Lymphoma; Obese